Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The role of liraglutide in the management of obesity

The role of liraglutide in the management of obesity Obesity has been defined as abnormal or excessive fat accumulation that may impair health. Obesity is associated with multiple comorbidities, affecting mechanical systems within the body as well as metabolic and mental health. If a person is overweight or obese, a loss of 5–10% of total body weight can have a number of health advantages. In the UK, there are three medications approved by the European Medicines Agency (EMA) for weight loss: orlistat, liraglutide and naltrexone in combination with bupropion. Liraglutide has the proprietary name Saxenda (Novo Nordisk). It may be prescribed for individuals with a body mass index (BMI) of 30 kg/m2 or more or people with a BMI of 27 kg/m2 who have another weight-related illness, such as high blood pressure, type 2 diabetes or dyslipidaemia. As with many weight-management programmes, liraglutide works in conjunction with a reduced-calorie diet and increased physical activity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Aesthetic Nursing Mark Allen Group

The role of liraglutide in the management of obesity

Journal of Aesthetic Nursing , Volume 8 (7): 5 – Sep 2, 2019

Loading next page...
 
/lp/mark-allen-group/the-role-of-liraglutide-in-the-management-of-obesity-rwZ3fwt43g
Publisher
Mark Allen Group
Copyright
Copyright © 2019 MA Healthcare Limited
ISSN
2050-3717
eISSN
2052-2878
DOI
10.12968/joan.2019.8.7.322
Publisher site
See Article on Publisher Site

Abstract

Obesity has been defined as abnormal or excessive fat accumulation that may impair health. Obesity is associated with multiple comorbidities, affecting mechanical systems within the body as well as metabolic and mental health. If a person is overweight or obese, a loss of 5–10% of total body weight can have a number of health advantages. In the UK, there are three medications approved by the European Medicines Agency (EMA) for weight loss: orlistat, liraglutide and naltrexone in combination with bupropion. Liraglutide has the proprietary name Saxenda (Novo Nordisk). It may be prescribed for individuals with a body mass index (BMI) of 30 kg/m2 or more or people with a BMI of 27 kg/m2 who have another weight-related illness, such as high blood pressure, type 2 diabetes or dyslipidaemia. As with many weight-management programmes, liraglutide works in conjunction with a reduced-calorie diet and increased physical activity.

Journal

Journal of Aesthetic NursingMark Allen Group

Published: Sep 2, 2019

There are no references for this article.